NICE has issued a final appraisal determination recommending Celgene's Otezla for adults with active psoriatic arthritis, reversing an earlier decision to reject the drug. The oral drug is Celgene ...
Otezla was acquired by Amgen for $13.4 billion when Celgene was forced by regulators to offload the drug ahead of its merger with BMS in late 2019, on fears that having both Otezla and ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback